<DOC>
	<DOCNO>NCT03082144</DOCNO>
	<brief_summary>It prove concurrent radiotherapy ( RT ) intrathecal methotrexate ( MTX ) leptomeningeal metastasis ( LM ) solid tumor adverse prognostic factor show great effectiveness safety . Cytarabine ( Ara-C ) another agent commonly use intrathecal chemotherapy . The purpose study observe effectiveness safety concurrent RT intrathecal chemotherapy LM solid tumor . In addition , effectiveness two type agent ( MTX Ara-C ) concurrent chemo-radiotherapy compare study . This randomize control , parallel group , phase II clinical trial . The object study newly diagnosis patient leptomeningeal metastasis solid tumor , accept treatment involved-field RT combine concurrent intrathecal-MTX intrathecal-Ara-C , respectively . Major endpoint clinical response rate . Secondary endpoint time progression , severe adverse event overall survival .</brief_summary>
	<brief_title>Concurrent Involved-field Radiotherapy Intrathecal Chemotherapy Leptomeningeal Metastases From Solid Tumors</brief_title>
	<detailed_description>The patient randomly divide two group , accept treatment involved-field RT combine concurrent intrathecal-MTX intrathecal-Ara-C , respectively . Concomitant regimen consist intrathecal chemotherapy ( via lumbar puncture , MTX 15 mg , plus dexamethasone 5 mg , Ara-C 50mg , plus dexamethasone 5 mg , per week , 4 week total ) RT . RT consist fractionate , conformal radiation give daily dose 2 Gy . The planning volume consist site symptomatic disease , bulky disease observe MRI , include whole brain basis cranii receive 40 Gy 20 fraction and/or segment spinal canal receive 40-50 Gy . In investigator 's previous study , criterion evaluation clinical response establish base improvement neurologic symptoms/signs change karnofsky performance status ( KPS ) . The criterion prove effective method evaluation prognosis . The method use assess clinical response study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>1 . Patients definitely diagnosed leptomeningeal metastasis accord cerebrospinal fluid cytology neuroimaging , patient get clinical diagnosis combine history cancer , clinical manifestation , cerebrospinal fluid examination , neuroimaging etc ; 2 . Patients diagnose malignant solid tumor definite pathologic type , exclude hematological malignancy ( e.g. , leukemia lymphoma ) primary brain tumor ; 3 . No severe abnormal liver kidney function ; WBC≥2500/mm3 , Plt≥60000/mm3 ; 4 . No severe chronic disease ; 5 . No history severe nervous system disease ; 6 . No severe dyscrasia ; 7 . Signed informed consent form . 1 . Patients leptomeningeal metastasis unknown primary tumor ; 2 . Patients receive radiotherapy brain past 6 month ; 3 . Patients accept systemic chemotherapy within one month treatment , molecular target therapy le 3 month ; 4 . Patients poor compliance , reason , researcher consider unsuitable participate clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>